comparemela.com

Latest Breaking News On - Molly cogan - Page 1 : comparemela.com

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions

Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat.

Stephen willardMolly coganNrx pharmaceuticals inc nasdaqGlobal communicationsDrug administrationNrx pharmaceuticals incNrx pharmaceuticalsTrademark officeNrxp nrx pharmaceuticalsUs food drug administrationNeurorx incChief executive officerBreakthrough therapy designationProtocol agreementSub acute suicidalitySpecial protocol agreement

NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior

/PRNewswire/ NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today reported the.

United statesStephen willardMolly coganGlobal communicationsNrxp nrx pharmaceuticalsCompany bipolar depressionNrx pharmaceuticals incNrx pharmaceuticalsIndependent data safety monitoring boardSerious adverse eventsData safety monitoring boardSevere bipolar depressionSubacute suicidal ideationBipolar depressionAcute suicidal ideationColumbia suicide severity rating scale

NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

/PRNewswire/ NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS).

United statesStephen willardMolly coganGlobal communicationsDrug administrationNrx pharmaceuticals incNrx pharmaceuticalsGovernment affairsNrxp nrx pharmaceuticalsWritten responsesBreakthrough therapy designationSpecial protocol agreementBipolar depressionAcute suicidal ideationProtocol agreementSub acute suicidality

NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J P Morgan Healthcare Conference

/PRNewswire/ NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced.

United statesSan franciscoMolly coganGlobal communicationsNeuroscience innovation forumPrnewswire nrx pharmaceuticals incNrx pharmaceuticals incNrx pharmaceuticalsSachs associatesGovernment affairsNrxp nrx pharmaceuticalsAnnual neuroscience innovation forumHealthcare conferenceProtocol agreementBreakthrough therapy designationSub acute suicidality

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality

First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received.

United statesStephen willardSuzanne messereMolly coganGlobal communicationsCompany phasePrnewswire nrx pharmaceuticals incNrx pharmaceuticals incNrx pharmaceuticalsPsychiatry divisionGovernment affairsNrxp nrx pharmaceuticalsSevere bipolar depressionAcute suicidalBreakthrough therapy designationSpecial protocol assessment

vimarsana © 2020. All Rights Reserved.